SCHEMBL3560164

SCHEMBL3560164

CCOC(=O)/C(=C\N(C)C)C(=O)c1cccc2ccccc12

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC25B P30305 2/20 0.52
ALDH1A1 P00352 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CDC25A P30304 1/20 0.46
CDC25C P30307 1/20 0.46
MEN1 O00255 3/20 0.46
KMT2A Q03164 3/20 0.46
HPGD P15428 1/20 0.44
CA12 O43570 1/20 0.43
CA2 P00918 1/20 0.43
CA9 Q16790 1/20 0.43
NR4A1 P22736 1/20 0.41
NR4A2 P43354 1/20 0.41
NR4A3 Q92570 1/20 0.41
TSHR P16473 1/20 0.41
GAA P10253 2/20 0.40
CNR1 P21554 1/20 0.40
MAPT P10636 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
PTPN1 P18031 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3560168 1.00 CDC25B (0.52) CDC25BALDH1A1KDM4ECDC25ACDC25C
SCHEMBL6016616 1.00 CDC25B (0.52) CDC25BALDH1A1KDM4ECDC25ACDC25C
SCHEMBL3570354 0.83 KMT2A (0.50) ALDH1A1KDM4EMEN1KMT2ATSHR
SCHEMBL3570355 0.83 KMT2A (0.50) ALDH1A1KDM4EMEN1KMT2ATSHR
SCHEMBL697232 0.83 CDC25B (0.63) CDC25BALDH1A1KDM4ECDC25ACDC25C
SCHEMBL2953731 0.81 CYP11B1 (0.50) ALDH1A1KDM4EMEN1KMT2ATSHR
SCHEMBL3565281 0.81 MEN1 (0.48) ALDH1A1MEN1KMT2AHPGDTSHR
SCHEMBL2953727 0.81 CYP11B1 (0.50) ALDH1A1KDM4EMEN1KMT2ATSHR
SCHEMBL955148 0.81 CYP11B1 (0.52) ALDH1A1MEN1KMT2AHPGDTSHR
SCHEMBL29398562 0.81 CYP11B1 (0.50) ALDH1A1KDM4EMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825278-B2 Substituted enaminones, their derivatives and uses thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-11-02 US disclosed
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof OXFORD FINANCE CORPORATION 2008-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080064748-A1 Substituted enaminones, their derivatives and uses thereof GABRB2, GABRB1, GABRB3 CDC25B 4622/4885ALDH1A1 423/4885KDM4E 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.